Safety of anticoagulant treatment in cancer patients

Bibliography

• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6):715-22
   PubMed Web of Science ®Google Scholar
• White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165(15):1782-7
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. risk analysis using medicare claims data. Medicine (Baltimore) 1999;78(5):285-91
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110(10):2339-46
   PubMed Web of Science ®Google Scholar
• Walker AJ, West J, Card TR, et al. Variation in the risk of venous thromboembolism in people with colorectal cancer: A population-based cohort study from england. J Thromb Haemost 2014;12(5):641-9
   PubMed Web of Science ®Google Scholar
• Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked united kingdom databases. Eur J Cancer 2013;49(6):1404-13
   PubMed Web of Science ®Google Scholar
• Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J Thromb Haemost 2006;4(3):529-35
   PubMed Web of Science ®Google Scholar
• Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458-64
   PubMed Web of Science ®Google Scholar
• Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med 2000;160(6):769-74
   PubMed Web of Science ®Google Scholar
• Heit JA, Mohr DN, Silverstein MD, et al.J,3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 2000;160(6):761-8
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902-7
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;9;116(24):5377-82
   PubMed Web of Science ®Google Scholar
• Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res 2012;129(Suppl 1):S6-9
   PubMedGoogle Scholar
• Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25(34):5490-505
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, Samama MM. American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e24S-43S
   PubMed Web of Science ®Google Scholar
• Siegal DM, Garcia D. Anticoagulants in cancer. J Thromb Haemost 2012;10(11):2230-41
   PubMed Web of Science ®Google Scholar
• Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e495S-530S
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Rojan A, Campigotto F, et al. Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: A prospective, cross-sectional, multicenter study. J Clin Oncol 2014;32(17):1792-6
   PubMed Web of Science ®Google Scholar
• Kleinjan A, Aggarwal A, Van de Geer A, et al. A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thromb Haemost 2013;110(5):959-65
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484-8
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2013;31(17):2189-204
   PubMed Web of Science ®Google Scholar
• Prommer E. Management of bleeding in the terminally ill patient. Hematology 2005;10(3):167-75
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP, et al. Disseminated intravascular coagulation in solid tumors: Clinical and pathologic study. Thromb Haemost 2001;86(3):828-33
   PubMed Web of Science ®Google Scholar
• Prandoni P, Siragusa S, Girolami B, Fabris F. BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: A prospective cohort study. Blood 2005;106(9):3049-54
   PubMed Web of Science ®Google Scholar
• Burbury KL, Seymour JF, Dauer R, Westerman DA. Under-recognition of platelet dysfunction in myelodysplastic syndromes: Are we only seeing the tip of the iceberg? Leuk Lymphoma 2013;54(1):11-13
   PubMed Web of Science ®Google Scholar
• Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8(1):202-4
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Porreca E, Otten HM, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2014;8:CD008500
   PubMedGoogle Scholar
• Wester JP, de Valk HW, Nieuwenhuis HK, et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost 1996;76(5):682-8
   PubMed Web of Science ®Google Scholar
• Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. findings from the RIETE registry. Thromb Haemost 2008;100(1):26-31
   PubMed Web of Science ®Google Scholar
• Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 2000;18(17):3078-83
   PubMed Web of Science ®Google Scholar
• Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. findings from the RIETE registry. Thromb Haemost 2008;100(3):435-9
   PubMed Web of Science ®Google Scholar
• Chee CE, Ashrani AA, Marks RS, et al.J,3rd, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: A population-based cohort study. Blood 2014;123(25):3972-8
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12(4):389-96
   PubMed Web of Science ®Google Scholar
• Lee AY, Kamphuisen PW, Meyer G, et al. A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood. 2014;124(21):LBA-2
   Google Scholar
• Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 2002;162(15):1729-35
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-53
   PubMed Web of Science ®Google Scholar
• Hull RD, PineoBrant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119(12):1062-72
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials. Blood 2014;124(12):1968-75
   PubMed Web of Science ®Google Scholar
• Larsen TB, Nielsen PB, Skjoth F, et al. Non-vitamin k antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: A semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS ONE 2014;9(12):e114445
   PubMedGoogle Scholar
• Suryanarayan D, Schulman S. Potential antidotes for reversal of old and new oral anticoagulants. Thromb Res 2014 May;133(Suppl 2):S158-66
   PubMedGoogle Scholar
• van Ryn J, Schurer J, Kink-Eiband M, Clemens A. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology 2014;120(6):1429-40
   PubMed Web of Science ®Google Scholar
• Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349(7):631-9
   PubMed Web of Science ®Google Scholar
• Carrier M, Khorana AA, Zwicker J, et al. Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH. J Thromb Haemost 2013;11(9):1760-5
   PubMed Web of Science ®Google Scholar
• Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012;126(4):448-54
   PubMed Web of Science ®Google Scholar
• Romera A, Cairols MA, Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009;37(3):349-56
   PubMed Web of Science ®Google Scholar
• Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014;7:CD006650
   PubMedGoogle Scholar
• Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013;11(1):56-70
   PubMed Web of Science ®Google Scholar
• Imberti D, Di Nisio M, Donati MB, et al. Treatment of venous thromboembolism in patients with cancer: Guidelines of the italian society for haemostasis and thrombosis (SISET). Thromb Res 2009;124(5):e32-40
   PubMedGoogle Scholar
• Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009;7(5):760-5
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22(10):1944-8
   PubMed Web of Science ®Google Scholar
• Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23(10):2123-9
   PubMed Web of Science ®Google Scholar
• Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2(8):1266-71
   PubMed Web of Science ®Google Scholar
• Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23(10):2130-5
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10(10):943-9
   PubMed Web of Science ®Google Scholar
• van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29(15):2071-6
   PubMed Web of Science ®Google Scholar
• Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366(7):601-9
   PubMed Web of Science ®Google Scholar
• Noble S. Heparins and cancer survival: Where do we stand? Thromb Res 2014;133(Suppl 2):S133-8
   PubMedGoogle Scholar
• Akl EA, Kahale LA, Ballout RA, et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst Rev 2014;12:CD006652
   PubMedGoogle Scholar
• Lee AY. Treatment of established thrombotic events in patients with cancer. Thromb Res 2012;129(Suppl 1):S146-53
   PubMedGoogle Scholar